Peptide Therapy for CIRS

Chronic Inflammatory Response Syndrome, also called CIRS, is difficult to untangle. Patients may be dealing with ongoing environmental exposure, immune activation, hormonal disruption, nervous system stress, and digestive concerns all at once. That complexity is one reason why a thoughtful, stepwise approach matters so much.

Peptides have become a popular topic in functional medicine, but they are not a first step for every CIRS patient. When the underlying biotoxin burden has not been addressed, even promising therapies feel unpredictable or ineffective. A careful sequence, guided by clinical testing and patient tolerance, is what makes peptide therapy more useful and more appropriate.

Why CIRS Requires a Sequenced Approach

CIRS is not just a single symptom or a single diagnosis. It is a multi-system response that involves inflammation, fatigue, brain fog, sleep issues, sinus problems, hormone changes, and reduced resilience. Because the condition affects so many systems at once, treatment often works best when it is organized in phases rather than approached all at the same time.

Many patients are understandably eager to feel better quickly. However, if the root triggers are still present, introducing advanced therapies too early leads to setbacks. In a functional medicine setting, the goal is to reduce the overall inflammatory burden first, then support repair and recovery in a way that matches the patient’s readiness.

Where Peptides Fit in CIRS Care

Peptides are short chains of amino acids that signal specific biological responses in the body. In CIRS care, they may be used to support immune regulation, tissue repair, neurological recovery, mitochondrial function, and inflammatory balance. The key is knowing when to use them and which peptide is appropriate for the phase of care.

It is a common mistake to think of peptides as the starting point. In reality, they are more often part of a later-stage strategy. Later sequencing helps reduce the risk of flares and improves the odds of a meaningful response.

1. Remove the source of exposure

The first priority in CIRS is to get the patient out of the water-damaged or moldy environment. If exposure is ongoing, no treatment plan will fully succeed because the immune system remains under constant pressure. Environmental remediation, relocation, and careful exposure reduction are foundational steps before more advanced therapies are considered.

2. Bind and clear circulating mycotoxins

Once exposure is reduced, clinicians often focus on clearing biotoxins that continue to circulate through the body. Binders such as cholestyramine or Welchol are commonly used to help interrupt the enterohepatic recirculation of mycotoxins. This step is important because lowering the toxin load makes the rest of the treatment plan more tolerable and more effective.

3. Address MARCoNS and biofilm-related infection

Many CIRS patients also struggle with MARCoNS, which refers to multiple antibiotic-resistant coagulase-negative staphylococci in the nasal passages. BEG spray is a commonly used option in this phase, and it is also where certain peptides may begin to enter the picture. LL-37 and PN5 are often discussed here because they support antimicrobial activity, biofilm disruption, and innate immune response in a more targeted way.

These peptides are notable because they may be incorporated earlier than others when a biofilm-based infectious component is clearly part of the clinical picture. Even then, they are best used with careful oversight, especially in patients who are highly reactive or who have not yet stabilized from the upstream burden of exposure and toxin load.

Common Peptides For CIRS Support

Once the foundational pieces are in place, peptide therapy is tailored to the patient’s symptoms and recovery stage. Some peptides are used to support inflammation control, while others may help with nervous system balance, repair of the gut lining, or mitochondrial recovery. The following options are often discussed in a CIRS-informed functional medicine framework:

• SS-31, TA1, Semax, Selank, and VIP for neurological and immune inflammation support
• BPC-157, KPV, and TB-500 for tissue repair and gut or connective tissue recovery
• MOTS-c, ARA-290, and Cerebrolysin for mitochondrial and cognitive support as the patient stabilizes
• LL-37 and PN5 for earlier antimicrobial and biofilm-focused support when clinically appropriate

These peptides are not interchangeable, and they are not all used for the same purpose. Their role depends on the patient’s overall picture, including symptom pattern, inflammatory markers, infection burden, and how well the person is tolerating treatment. That is why personalization matters so much in CIRS care.

Hormones, Signaling, and Recovery After CIRS

CIRS affects more than immune function. Many patients also show disruption in signaling pathways and hormone-related markers. These markers help clinicians understand how deeply the syndrome has affected the body and where recovery is still needed.

As these systems begin to normalize, some patients notice improvements in sleep, energy, focus, temperature regulation, and overall resilience. That said, hormone and signaling support should always be interpreted within the broader clinical context. Addressing the root inflammatory burden remains central to lasting progress.

Why Timing Matters With Peptide Therapy for CIRS

In CIRS, timing makes the difference between a helpful intervention and a frustrating one. If a patient starts a peptide too early, the body may react strongly because the inflammatory environment is still too active. This creates the impression that the peptide is “not working,” when in fact the problem is the sequence, not necessarily the tool itself.

A Shoemaker-informed framework helps clinicians decide when to move from detoxification and infection management into repair and recovery. This approach is especially useful for patients who have tried multiple therapies without sustained results. When the phases are respected, treatment feels more manageable and much less reactive.

Candidate considerations for peptide therapy

Before peptides are added, patients should have removed or significantly reduced environmental exposure and completed the earliest phases of biotoxin clearance. CIRS patients are often unusually sensitive, so even a well-chosen peptide may cause a flare if the body is not ready. A slower, more measured strategy is often safer and more effective than trying to do too much at once.

LL-37 and PN5 are a special case because they may be used earlier to help address the infectious or biofilm component. Outside of that situation, most peptides are better suited for later phases, after the foundation has been established. This allows the clinician to support recovery rather than create additional stress on an already burdened system.

How In2GREAT Approaches Peptide Therapy for CIRS

At In2GREAT, peptide therapy for CIRS is considered within the context of the whole patient, not as a stand-alone fix. That means looking at exposure history, inflammatory patterns, gut function, nervous system symptoms, and key lab markers before deciding on the next step.

For patients dealing with suspected or confirmed CIRS, this individualized approach can create a clearer path forward. The goal is not to force the body into recovery, but to remove obstacles and support each phase in the right order.

If you are looking for a thoughtful, functional medicine approach to peptide therapy for CIRS, In2GREAT can help you get started.